— Latest update: May 2022 —
With an ever-increasing number of bio-ventures and the establishment of a new ecosystem in the Japanese biotech field, this sector offers many opportunities for European SME companies. Through industrial, academic, government and international collaboration, various programs are being promoted and implemented. Due to Japan’s population aging and the resulting health issues, the pharmaceutical sector remains an especially attractive market, as evidenced by the high number of deals between European investors and Japanese biopharma in 2021.
JBA, 2021 Activity Report
EU-Japan Centre, Report : Japan Bioventures Landscape, 2018
JETRO, Life Sciences: Attractive Sectors, 2021
Table of Contents
The EU-Japan Centre currently produces 5 newsletters :